Last reviewed · How we verify
Herpes simplex infection of skin — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zovirax | ACYCLOVIR | Ligand Pharms | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | Purine nucleoside phosphorylase | 1982-01-01 | |
| Aciclovir | Aciclovir | Assistance Publique Hopitaux De Marseille | Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase | |||
| ACYC | ACYC | Ligand Pharms | Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Ligand Pharms · 2 drugs in Herpes simplex infection of skin
- Assistance Publique Hopitaux De Marseille · 1 drug in Herpes simplex infection of skin
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Herpes simplex infection of skin:
- Herpes simplex infection of skin treatment updates — RSS
- Herpes simplex infection of skin treatment updates — Atom
- Herpes simplex infection of skin treatment updates — JSON
Cite this brief
Drug Landscape (2026). Herpes simplex infection of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/herpes-simplex-infection-of-skin. Accessed 2026-06-10.
Related
- Herpes simplex infection of skin full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing